Colonoscopy With Ulcerative Colitis: When and How Often

← Patient Education

A colonoscopy with ulcerative colitis does two jobs. It shows how active the inflammation is, and over the long term it is the main way to find precancerous changes in the colon early, when they can often be removed. The same is true for Crohn's disease that involves the colon. This kind of exam is called surveillance colonoscopy, and its schedule is different from the routine screening most adults start at 45. This page explains when surveillance usually begins, how often it repeats, what happens during the exam, and what the results can mean, based on current guidance from the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), and the American Cancer Society.

This article is general education, not medical advice. Your own surveillance schedule depends on your disease, your history, and your gastroenterologist's judgment.

Why a colonoscopy with ulcerative colitis is different

Ulcerative colitis and Crohn's disease are the two main forms of inflammatory bowel disease (IBD). When either one affects the colon for many years, the ongoing inflammation raises the risk of colorectal cancer. The 2025 ACG ulcerative colitis guideline describes this as a defined risk of dysplasia and cancer that is believed to come mainly from more extensive bowel involvement and longstanding inflammation.

Dysplasia means cells in the lining of the colon that look abnormal under the microscope. It is not cancer, but it is the stage before cancer, and finding it is the point of surveillance. In people without IBD, most colon cancers start as a polyp that sticks up from the lining and is easy to spot. In colitis, precancerous areas can be flat, subtle, or hidden among inflamed or scarred tissue. That is why a colonoscopy with ulcerative colitis takes more time, follows a more careful technique, and often includes more biopsies than a standard screening exam.

The American Cancer Society states that people with IBD generally need colonoscopy, not any other type of test. Stool tests and other screening options used for average-risk adults are not a substitute.

The guidelines behind this page

The main U.S. source on this topic is the AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases, published in Gastroenterology in September 2021. It contains 14 practice advice statements, and it remains the AGA's current document on the subject. Two newer ACG guidelines, both published in June 2025, add to it:

• The ACG Crohn's disease guideline includes a strong recommendation, based on moderate-quality evidence, for routine surveillance colonoscopy in people with Crohn's colitis.
• The ACG ulcerative colitis guideline update states that it did not address endoscopic surveillance and that the topic will be covered in a future ACG guideline. It does note that controlling inflammation in the lining of the colon may reduce dysplasia risk.

The American Cancer Society screening page, last revised in May 2026, gives a simpler summary for the public, which is described below. The numbers differ slightly between sources, and this page says so where they do.

When to start a colonoscopy with ulcerative colitis or Crohn's colitis

The AGA advises that the first colonoscopy aimed at finding dysplasia should be done 8 to 10 years after diagnosis in everyone with IBD that involves the colon. The American Cancer Society puts it as starting at least 8 years after diagnosis.

For Crohn's disease, the ACG 2025 guideline suggests surveillance for people who have had the disease for at least 8 years with more than 30% of the colon involved. It notes that risk rises with both how long the disease has been present and how much of the colon it affects, and that a Crohn's diagnosis before age 40 is also associated with higher risk. The ACG points to a study of 23,751 colonoscopies in people with IBD in which dysplasia progressed at a similar rate in Crohn's disease and ulcerative colitis, which supports using similar surveillance strategies for both.

The clock starts from diagnosis, not from age. A person diagnosed with ulcerative colitis at 22 may be due for a first surveillance exam around 30, long before routine screening would begin. If you are not sure when your disease was diagnosed, or your records are from another practice, bring what you have so your physician can estimate the date.

Primary sclerosing cholangitis changes the timing

Primary sclerosing cholangitis, or PSC, is a liver disease that scars the bile ducts and is strongly linked to ulcerative colitis. Both the AGA and the ACG advise starting surveillance colonoscopy at the time PSC is diagnosed, rather than waiting 8 to 10 years, and the ACG adds that this applies regardless of how much of the colon is involved. Our page on autoimmune liver disease covers PSC in more detail.

How often a colonoscopy with ulcerative colitis is repeated

After a first surveillance exam that shows no dysplasia, the AGA advises repeating colonoscopy every 1 to 5 years. The American Cancer Society gives a range of every 1 to 3 years. Both say the interval depends on the person's risk factors and on what earlier exams found.

The AGA lists the factors that move someone toward the shorter end of that range:

• How much inflammation the colon has now, and how much it has had in the past
• A family history of colorectal cancer
• Primary sclerosing cholangitis
• A history of dysplasia found on an earlier exam
• How often surveillance has been done before, and how good those exams were

The ACG Crohn's guideline names a similar set of risk factors for colorectal cancer in Crohn's colitis: how long the disease has been present, how much of the colon is involved, PSC, a family history of colorectal cancer, and how severe the ongoing inflammation is.

A practical point follows from that list. If an exam was hard to read because of a poor bowel prep or active inflammation, the next one may come sooner. A clean, well-prepared exam during a period of good disease control gives your physician the clearest view and the most confidence in a longer interval.

How family history fits in

A parent, sibling, or child with colorectal cancer adds to the risk that colitis already carries. Tell your gastroenterologist about any relatives with colon cancer or advanced polyps and the age at which they were diagnosed. Our page on family history and colon cancer screening explains how that history is gathered.

Getting ready for a colonoscopy with ulcerative colitis

The AGA advises optimizing the conditions for finding dysplasia before and during the exam. Its list includes controlling inflammation, using high-definition endoscopes, a good bowel preparation, and careful washing and inspection of the entire lining of the colon and rectum.

Timing the exam around disease activity

Active inflammation can make the lining look irregular and can make it harder for the pathologist to tell inflamed cells from dysplastic ones. Your gastroenterologist may prefer to schedule surveillance when the disease is under good control. If you are in a flare when your exam is due, ask whether it should go ahead or wait.

Bowel prep for a colonoscopy with ulcerative colitis

Because precancerous areas in colitis can be flat and subtle, a clean colon matters even more than usual. Follow the prep instructions closely, and tell the office in advance if past preps were hard to finish or if a flare makes the prep difficult. Our pages on colonoscopy prep and on what happens when a bowel prep is not adequate explain why the prep decides how much of the colon can be seen.

What happens during a colonoscopy with ulcerative colitis

The exam itself follows the same steps as any colonoscopy, including sedation and recovery, which our pages on what to expect from a colonoscopy and colonoscopy sedation describe. What differs is how the lining is examined and sampled.

Biopsies to map the disease

At the first surveillance exam, the AGA advises taking biopsies from several segments of the colon to measure how active the disease is and how far it extends. That extent helps set future intervals. The ACG ulcerative colitis guideline adds that biopsies should be taken from parts of the colon that look normal, because inflammation under the microscope can reach further than what is visible.

Targeted biopsies and removal of visible lesions

Any area that looks suspicious, or that looks different from the surrounding lining for no clear reason, should be biopsied. The AGA prefers removing a lesion outright, rather than only sampling it, when its edges are clear and it shows no signs of invasive cancer. If it is uncertain whether a lesion can be removed safely during colonoscopy, the AGA suggests referral to a specialized endoscopist or an IBD center.

Chromoendoscopy and high-definition scopes

Chromoendoscopy is a technique that makes subtle changes in the lining easier to see. In dye spray chromoendoscopy, a blue dye is sprayed on the lining during the exam to outline its surface. Virtual chromoendoscopy uses light filters built into the endoscope to do something similar without dye.

The AGA advises that dye spray chromoendoscopy, performed by trained endoscopists, be considered for everyone with colonic IBD having surveillance, especially if a standard-definition scope is used or there is a history of dysplasia. It calls virtual chromoendoscopy a suitable alternative when a high-definition scope is used. Which technique is right for you depends on your history and the equipment available, so it is a reasonable question to ask before the exam.

Random biopsies

When the exam is done with white light only, without either form of chromoendoscopy, the AGA advises taking many biopsies from flat-looking lining in areas that have had colitis, roughly four biopsies every 10 centimeters, plus extra samples from areas of past dysplasia or poor visibility. When chromoendoscopy is done with a high-definition scope, those routine random biopsies are not usually needed, though the AGA says they should still be considered for people with past dysplasia or PSC. This is one reason surveillance exams can take longer than a routine screening colonoscopy.

Pseudopolyps

Pseudopolyps are bumps of tissue left behind by past inflammation. They are not true polyps, but they can crowd the view. The AGA says biopsies of representative or concerning pseudopolyps are appropriate, while removing and sampling every one is neither required nor practical. It also notes that dye spray chromoendoscopy should not be used to look for flat lesions within a field of pseudopolyps.

Understanding results after a colonoscopy with ulcerative colitis

Your report will usually describe how active the inflammation is, how far it extends, and anything that was biopsied or removed. Pathology results on any biopsies follow after the exam. Our page on colonoscopy results explains common report terms, although surveillance intervals for IBD follow the IBD-specific guidance on this page rather than the polyp tables used for average-risk adults.

How dysplasia is described

The AGA advises describing precancerous areas in IBD as polypoid (raised 2.5 millimeters or more), nonpolypoid (raised less than 2.5 millimeters), or invisible (found only on a random biopsy). It advises abandoning older terms such as DALM, adenoma-like mass, and flat dysplasia. If you have older reports that use those terms, your physician can translate them into the current categories.

What happens if dysplasia is found

Finding dysplasia does not automatically mean surgery. The AGA guidance describes several paths:

• A visible lesion that was fully removed: continued surveillance at shorter intervals is appropriate.
• Dysplasia found only on a random biopsy, with nothing visible: a repeat exam by an experienced endoscopist using high-definition dye spray chromoendoscopy, with many biopsies in the same area if no lesion is seen. If the repeat exam does not confirm dysplasia, continued frequent surveillance is appropriate.
• A visible lesion that cannot be removed, or invisible dysplasia that is high grade or found in more than one place: the AGA advises removal of the colon (colectomy).

These decisions are made with your gastroenterologist and, when surgery is under discussion, a colorectal surgeon.

Surveillance after colon surgery

Some people with ulcerative colitis have had their colon removed and an internal pouch built from the small intestine, called an ileal pouch. The AGA advises examining the pouch at least once a year for people at high risk of dysplasia, meaning those with prior colorectal cancer or dysplasia or with PSC, and for people with persistent moderate to severe inflammation of the pouch. For people at lower risk, the AGA says the interval should be individualized.

Can medication lower the cancer risk?

The AGA calls good disease control with medical therapy imperative to reducing a person's lifetime risk of colorectal cancer, and the ACG 2025 ulcerative colitis guideline says controlling inflammation may reduce dysplasia risk. The AGA also states that there is uncertainty about whether mesalamine, a common colitis medicine, has an independent cancer-preventing effect.

The practical message is that staying on effective treatment and keeping inflammation quiet supports both day-to-day health and long-term risk, but it does not replace surveillance. Do not start, stop, or change any IBD medication on your own. Our page on diet and IBD covers what the evidence says about food, which does not replace medicine either.

Insurance and scheduling

Surveillance colonoscopy is not the same as an average-risk screening exam, and insurers do not all classify it the same way. Some plans treat it as preventive and some as diagnostic. Our page on whether insurance covers a colonoscopy lists the questions to ask your plan before you schedule.

Preparing for a visit about a colonoscopy with ulcerative colitis

A visit to plan surveillance goes faster when you bring:

• The year you were diagnosed with ulcerative colitis or Crohn's disease, and how much of the colon was involved
• Reports and pathology results from past colonoscopies, especially any that mention dysplasia
• Whether you have been diagnosed with PSC or have had abnormal liver tests
• Relatives with colorectal cancer or advanced polyps, and their ages at diagnosis
• A current list of IBD medications and any recent changes
• Notes on past bowel preps that were hard to complete

Our page on your first gastroenterologist visit covers what else to bring.

Symptoms that should not wait for your next scheduled exam

Surveillance is planned in advance, but new symptoms should not wait for the next date on the calendar. Contact your gastroenterologist about a flare that does not settle, new or increased bleeding, unexplained weight loss, or a change in bowel habits that is different from your usual disease pattern. Heavy rectal bleeding, severe abdominal pain, fever with bloody diarrhea, or feeling faint is an emergency: call 911 or go to an emergency department.

IBD surveillance in Northern Virginia with GC of NoVA

Gastroenterology Center of Northern Virginia cares for adults with Crohn's disease and ulcerative colitis across Arlington, Annandale, and the surrounding communities. Our five gastroenterologists can review your history and past reports, work out when your next surveillance colonoscopy is due under current AGA and ACG guidance, and explain what the exam will involve. If you have moved to the area or your records are scattered, we can help you put the timeline back together. Our page on when to see a gastroenterologist can help you decide whether it is time.

We see patients at our Arlington office at 1715 N George Mason Drive, adjacent to VHC Health, and our Annandale office at 3299 Woodburn Road in the Woodburn Medical complex. To schedule a visit, call Arlington at (703) 522-7476 or Annandale at (703) 560-6106, or learn more at gcofnova.com.

This article is for general education and is not medical advice. Surveillance intervals described here are general guideline recommendations, and your own schedule depends on your disease, your history, and your physician's judgment. Talk with a qualified gastroenterologist about your situation.